Forecasts data is unavailable for this security.

Consensus recommendation

As of Jan 14, 2017, the consensus forecast amongst 28 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Share price forecast

The 23 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 93.00, with a high estimate of 135.00 and a low estimate of 74.29. The median estimate represents a 28.93% increase from the last price of 72.13.


In 2015, Gilead Sciences Inc reported a dividend of 1.29 USD. The 12 analysts covering the company expect dividends of 1.86 USD for the upcoming fiscal year, an increase of 43.95%.
Div growth (TTM)--
More ▼

Earnings history & estimates

On Nov 01, 2016, Gilead Sciences, Inc. reported 3rd quarter 2016 earnings of 2.75 per share. This result was in line with the consensus of the 21 analysts following the company and under-performed last year's 3rd quarter results by 14.60%.
The next earnings announcement is expected on Feb 07, 2017.
Average growth rate-3.67%
Gilead Sciences, Inc. reported annual 2015 earnings of 12.61 per share on Feb 02, 2016.
The next earnings announcement from Gilead Sciences, Inc. is expected the week of Feb 07, 2017.
Average growth rate+89.52%
More ▼

Revenue history & estimates

Gilead Sciences Inc. had 3rd quarter 2016 revenues of 7.50bn. This bettered the 7.45bn consensus of the 20 analysts covering the company. This was 9.58% below the prior year's 3rd quarter results.
Average growth rate-2.40%
Gilead Sciences Inc. had revenues for the full year 2015 of 32.64bn. This was 31.13% above the prior year's results.
Average growth rate+46.12%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.